Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Have Active Di

Prensa/medios de comunicación

Período2 oct. 2018

Cobertura de los medios

1

Cobertura de los medios

  • NombreEvaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Have Active Di
    Nombre/canal del medio de comunicaciónClinical Trials.gov
    Fecha2/10/18
    PersonasDiego Luis Saaibi Solano